Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Decrypting a Collagen’s Role in Schizophrenia

By Drug Discovery Trends Editor | March 14, 2016

Cortical neurons (red) form few inhibitory synapses (green) in the absence of collagen XIX (left), but synapse formation is restored by a signaling peptide derived from the protein's C-terminal region (right). Credit: Su et al., 2016A small peptide generated from a collagen protein may protect the brain from schizophrenia by promoting the formation of neuronal synapses, according to a paper published in The Journal of Cell Biology. The study, “Collagen-Derived Matricryptins Promote Inhibitory Nerve Terminal Formation in the Developing Neocortex” by Jianmin Su and colleagues, may lead to new approaches to treating the mental disorder.
 
The collagen family of extracellular matrix proteins performs numerous functions in the brain, and mutations in several family members cause neurological diseases in humans. How collagen XIX promotes normal brain function is unknown, but loss of the gene encoding this collagen has been linked to familial schizophrenia.
 
A team of researchers led by Michael Fox at Virginia Tech Carilion Research Institute has been closely examining collagen XIX. They found that collagen XIX-deficient mice display a number of schizophrenia-related symptoms, including an abnormal startle response and an increased susceptibility to seizures. Schizophrenia has previously been linked to defects in a particular type of interneuron. This interneuron dampens neuronal activity in the brain’s cortex by forming inhibitory synapses with the cell bodies of other neurons. These inhibitory synapses were lost in collagen XIX-deficient mice.
 
Like similar types of collagen, collagen XIX can be cleaved by extracellular protease enzyme to generate a small signaling peptide called a matricryptin. Jianmin Su and colleagues found that this peptide was sufficient to rescue the formation of inhibitory synapses in neuronal cultures prepared from collagen XIX-deficient mice, apparently by binding and activating a cell adhesion receptor called integrin α5β1.
 
Fox and colleagues now want to learn more about how collagen XIX’s matricryptin fragment promotes synapse formation. “We also want to investigate whether the peptide holds any therapeutic potential for any diseases that result for malformed or malfunctioning cortical interneurons,” Fox says.
 
Source: Rockefeller University

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50